Methyl 4-(Bromomethyl)-3-Methoxybenzoate CAS 70264-94-7 Zafirlukast Intermediate

Name: Methyl 4-(Bromomethyl)-3-Methoxybenzoate   CAS: 70264-94-7 Assay (HPLC): ≥98.0% Appearance: Pale Yellow Powder  Intermediate of Zafirlukast (CAS 107753-78-6) Antiasthmatic High Quality, Commercial Production  Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply, High Purity, Commercial Production  Chemical Name: Methyl 4-(Bromomethyl)-3-Methoxybenzoate  CAS: 70264-94-7
Item Specifications
Appearance Pale Yellow Powder
Assay / Analysis Method ≥98.0% (HPLC)
Loss on Drying ≤1.0%
Residue on Ignition ≤0.50%
Total Impurities ≤2.0%
Heavy Metals ≤20ppm
Test Standard Enterprise Standard
Usage Intermediate of Zafirlukast (CAS: 107753-78-6), Used as an antiasthmatic

Description:

Specifications:

Package & Storage:

Chemical Name Methyl 4-(Bromomethyl)-3-Methoxybenzoate
Synonyms 4-(Bromomethyl)-3-methoxybenzoic Acid Methyl Ester; Methyl 4-(Bromomethyl)-m-anisate; 4-(Bromomethyl)-m-anisic Acid Methyl Ester 
CAS Number 70264-94-7
CAT Number RF-PI437
Stock Status In Stock 
Molecular Formula C10H11BrO3
Molecular Weight 259.10 
Melting Point 92.0 to 94.0℃
Density  1.432
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Methyl 4-(Bromomethyl)-3-Methoxybenzoate (CAS 70264-94-7) is used as an intermediate of Zafirlukast (CAS: 107753-78-6). Zafirlukast is a highly selective and long-acting oral lys-LTs antagonist. Leukotrienes play an important role in the pathogenesis of asthma. These substances are peptides, being capable of selectively binding to LTC4, LTD4 and LTE4 receptor for antagonism of its effect, reducing the symptoms of asthma and improving lung function. This product is both a preventive agent of inflammation caused by asthma (being antagonistic to leukotriene proinflammatory activity) and a relief drug for bronchial asthma (be antagonistic to leukotriene induced bronchial smooth muscle contraction). The use of this product does not change the smooth muscle response to β2 receptors and has good efficacy in the treatment of bronchoconstriction caused by antigen, aspirin, exercise and cold air, being able to reduce the dosage of hormone and β2 receptor agonist.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours